Latest Aeras Stories
First clinical trial to test a new all-oral regimen for extensively drug-resistant TB; Nix-TB is a critical step in the development of a universal treatment for all types of TB NEW
TBA-354 is the first potential tuberculosis drug to advance to Phase 1 trial in six years NEW YORK, Feb.
Seven New Grant Investments for $15.3 Million to Tackle Malaria, Chagas Disease and Dengue, which is Dramatically on the Rise TOKYO, Sept.
STAND trial will test the first regimen designed to significantly shorten and simplify the treatment of drug-sensitive and drug-resistant TB SEATTLE, April 23, 2014 /PRNewswire-USNewswire/
Aeras releases TB Crisis Tracker on World TB Day ROCKVILLE, Md., March 24, 2014 /PRNewswire/ -- The tuberculosis epidemic continues
Reportbuyer.com just published a new market research report:
Canadian researchers have developed a new tuberculosis vaccine that could boost or perhaps replace the only existing way to immunize against the infection.
A new vaccine considered to be the most advanced for tuberculosis among more than a dozen now in trials has failed its study. Researchers said they were disappointed by the results of the study, which showed that the vaccine offered little to no protection at all from TB.
- An uxorious, effeminate, or spiritless man.
- A timorous, cowardly fellow.